Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Unit of Internal Medicine, Terni University Hospital, Terni, Italy.
Br J Haematol. 2023 Jun;201(5):851-856. doi: 10.1111/bjh.18726. Epub 2023 Mar 8.
The effectiveness of vaccination against SARS-CoV-2 in preventing COVID-19 or in reducing severe illness in subjects hospitalized for COVID-19 despite vaccination has been unequivocally shown. However, no studies so far have assessed if subjects who get COVID-19 despite vaccination are protected from SARS-CoV-2-induced platelet, neutrophil and endothelial activation, biomarkers associated with thrombosis and worse outcome. In this pilot study, we show that previous vaccination blunts COVID-19-associated platelet activation, assessed by circulating platelet-derived microvesicles and soluble P-selectin, and neutrophil activation, assessed by circulating neutrophil extracellular trap (NET) biomarkers and matrix metalloproteinase-9, and reduces COVID-19-associated thrombotic events, hospitalization in intensive-care units and death.
疫苗接种在预防 COVID-19 或降低因 COVID-19 住院的患者的重症方面的有效性已得到明确证实。然而，迄今为止，尚无研究评估接种疫苗后仍感染 COVID-19 的患者是否免受 SARS-CoV-2 诱导的血小板、中性粒细胞和内皮细胞激活的影响，这些标志物与血栓形成和预后不良有关。在这项初步研究中，我们表明，先前的疫苗接种可减轻 COVID-19 相关的血小板激活，通过循环血小板衍生的微泡和可溶性 P 选择素来评估，以及中性粒细胞的激活，通过循环中性粒细胞胞外诱捕网（NET）生物标志物和基质金属蛋白酶-9来评估，从而减少 COVID-19 相关的血栓事件、入住重症监护病房和死亡。
